ADIL

SEC source: 0001213900-26-101883 · ownership.xml · derivative · entry 1

Young Wendy B. · CIK 0002042847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,666

Underlying: Common Stock · 25,666 shares

Expires 2036-06-12

F1 · date: On June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, which grant was subject to stockholder approval of an amendment to the Issuer's 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder. The Issuer's stockholders approved the plan amendment on September 17, 2026 ("Stockholder Approval Date").

F1 · derivative.exercise_date: On June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, which grant was subject to stockholder approval of an amendment to the Issuer's 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder. The Issuer's stockholders approved the plan amendment on September 17, 2026 ("Stockholder Approval Date").

F2 · derivative.exercise_date: 2,138 shares subject to the stock option vested on the Stockholder Approval Date and the remaining 23,528 shares subject to the stock option shall vest in substantially equal installments over a 33-month period, beginning on October 12, 2026.

SEC source: 0001104659-26-084300 · tm2620655-1_4seq1.xml · nonDerivative · entry 2

Coastlands Capital LP · CIK 0002068530 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Coastlands Capital LP

Disclosed balance after: 388,308

F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

SEC source: 0001104659-26-084300 · tm2620655-1_4seq1.xml · nonDerivative · entry 1

Coastlands Capital LP · CIK 0002068530 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Coastlands Capital LP

Disclosed balance after: 387,075

F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

SEC source: 0001104659-26-082972 · tm2620210-1_4seq1.xml · nonDerivative · entry 2

Coastlands Capital LP · CIK 0002068530 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Coastlands Capital LP

Disclosed balance after: 385,075

F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

SEC source: 0001104659-26-082972 · tm2620210-1_4seq1.xml · nonDerivative · entry 1

Coastlands Capital LP · CIK 0002068530 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Coastlands Capital LP

Disclosed balance after: 383,375

F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

SEC source: 0001104659-26-079686 · tm2619520-1_4seq1.xml · nonDerivative · entry 1

Coastlands Capital LP · CIK 0002068530 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Coastlands Capital LP

Disclosed balance after: 373,322

F1 · ownership.nature: Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

SEC source: 0001213900-26-069021 · ownership.xml · derivative · entry 1

Young Wendy B. · CIK 0002042847 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,378

Underlying: Common Stock · 36,378 shares

Expires not disclosed

F1 · kind: Pursuant to the terms of that certain Pre-Funded Warrant to Purchase Common Stock, dated June 12, 2026, issued by the Issuer to the Reporting Person pursuant to a securities purchase agreement entered into by and among the Issuer, the Reporting Person and certain other parties on June 11, 2026.

F2 · derivative.exercise_date: The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after receiving approval of the Issuer's stockholders. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

F2 · derivative.expiration_date: The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after receiving approval of the Issuer's stockholders. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

SEC source: 0001213900-26-069037 · ownership.xml · derivative · entry 6

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,417

Underlying: Common Stock · 232,417 shares

Expires 2036-06-12

F7 · kind: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

F7 · price: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

F7 · derivative.exercise_date: The stock option will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 3

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 297,491

F4 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in substantially equal consecutive monthly increments over a 36-month period beginning on July 12, 2026.

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 5

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Matt and Alli Davidson Trust

Disclosed balance after: 1,923.428

F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3 · kind: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F5 · kind: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3 · price: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F5 · price: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

F6 · ownership.nature: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 4

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,822.13

F1 · kind: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F5 · kind: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

F1 · price: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F5 · price: Each share of Series A Preferred Stock is convertible into 1,000 shares of the Issuer's common stock automatically following stockholder approval and satisfaction of certain Nasdaq listing standards, subject to certain beneficial ownership and other limitations, as set forth in the Certificate of Designation of the Series A Preferred Stock.

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 2

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Matt and Alli Davidson Trust

Disclosed balance after: 3,427

F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3 · kind: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F3 · shares: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F3 · price: Received in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 of Series A-2 Preferred Stock of Azora, pursuant to the terms of the Merger Agreement.

F6 · ownership.nature: The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

SEC source: 0001213900-26-069037 · ownership.xml · nonDerivative · entry 1

Davidson Matt · CIK 0001741937 · Director · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,647

F1 · kind: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2 · kind: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

F1 · shares: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F1 · price: Received in exchange for 5,902,500 shares of common stock of Azora Therapeutics, Inc. ("Azora"), pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Azora.

F2 · price: Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Azora, with Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Azora were converted into the right to receive shares of the Issuer's common stock and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

SEC source: 0001213900-26-042053 · ownership.xml · nonDerivative · entry 1

Shah Vinay · CIK 0001753078 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,325

F1 · shares: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC source: 0001213900-26-042054 · ownership.xml · nonDerivative · entry 1

Goodman Tony · CIK 0001717971 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,523

F1 · shares: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC source: 0001213900-26-042050 · ownership.xml · nonDerivative · entry 1

Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,417

F1 · shares: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC source: 0001213900-26-042055 · ownership.xml · derivative · entry 1

Anderson J. Kermit · CIK 0001717983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,185

Underlying: Common Stock · 9,185 shares

Expires 2036-04-06

F1 · derivative.exercise_date: The option vests in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC source: 0001213900-26-042052 · ownership.xml · nonDerivative · entry 1

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,213

F1 · shares: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC source: 0001213900-26-042051 · ownership.xml · nonDerivative · entry 1

Gilliland Robertson H. · CIK 0001718351 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,185

F1 · shares: Represents a grant of restricted shares of common stock that vest in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.

SEC source: 0001213900-25-050019 · ownership.xml · derivative · entry 1

Shah Vinay · CIK 0001753078 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2035-05-28

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

SEC source: 0001213900-25-050016 · ownership.xml · derivative · entry 1

Goodman Tony · CIK 0001717971 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,000

Underlying: Common Stock · 94,000 shares

Expires 2035-05-28

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

SEC source: 0001213900-25-050017 · ownership.xml · derivative · entry 1

Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,000

Underlying: Common Stock · 138,000 shares

Expires 2035-05-28

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

SEC source: 0001213900-25-050021 · ownership.xml · derivative · entry 1

Gilliland Robertson H. · CIK 0001718351 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2035-05-28

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

SEC source: 0001213900-25-050020 · ownership.xml · derivative · entry 1

Newman James W. Jr. · CIK 0001718364 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2035-05-28

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

SEC source: 0001213900-25-050018 · ownership.xml · derivative · entry 1

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2035-05-28

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

SEC source: 0001213900-25-050015 · ownership.xml · derivative · entry 1

Anderson J. Kermit · CIK 0001717983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2035-05-28

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

SEC source: 0001213900-24-106119 · ownership.xml · derivative · entry 1

Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2034-12-04

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing December 5, 2024.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing December 5, 2024.

SEC source: 0001213900-24-099632 · ownership.xml · derivative · entry 1

Shah Vinay · CIK 0001753078 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-11-15

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months.

SEC source: 0001213900-24-026706 · ownership.xml · derivative · entry 1

Goodman Tony · CIK 0001717971 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2034-03-24

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

SEC source: 0001213900-24-026714 · ownership.xml · derivative · entry 1

Truluck Joseph · CIK 0001718091 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-03-24

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

SEC source: 0001213900-24-026712 · ownership.xml · derivative · entry 1

Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-03-24

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

SEC source: 0001213900-24-026725 · ownership.xml · derivative · entry 1

Gilliland Robertson H. · CIK 0001718351 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2034-03-24

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

SEC source: 0001213900-24-026724 · ownership.xml · derivative · entry 1

Newman James W. Jr. · CIK 0001718364 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2034-03-24

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

SEC source: 0001213900-24-026711 · ownership.xml · derivative · entry 1

Anderson J. Kermit · CIK 0001717983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2034-03-24

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

SEC source: 0001213900-24-026708 · ownership.xml · derivative · entry 1

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2034-03-24

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024.

SEC source: 0001013762-23-000757 · ownership.xml · nonDerivative · entry 1

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 700

F1 · price: The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.72 through $2.78, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001213900-23-043117 · ownership.xml · derivative · entry 1

Goodman Tony · CIK 0001717971 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-05-23

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

SEC source: 0001213900-23-043129 · ownership.xml · derivative · entry 2

Stilley William B. III · CIK 0001718069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-05-23

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

SEC source: 0001213900-23-043129 · ownership.xml · nonDerivative · entry 1

Stilley William B. III · CIK 0001718069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,261,779

SEC source: 0001213900-23-043133 · ownership.xml · derivative · entry 2

Truluck Joseph · CIK 0001718091 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2033-05-23

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

SEC source: 0001213900-23-043133 · ownership.xml · nonDerivative · entry 1

Truluck Joseph · CIK 0001718091 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,139

SEC source: 0001213900-23-043111 · ownership.xml · derivative · entry 2

Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2033-05-23

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

SEC source: 0001213900-23-043111 · ownership.xml · nonDerivative · entry 1

Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,520,000

SEC source: 0001213900-23-043125 · ownership.xml · derivative · entry 1

Schuyler Kevin · CIK 0001718094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-05-23

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

SEC source: 0001213900-23-043114 · ownership.xml · derivative · entry 1

Gilliland Robertson H. · CIK 0001718351 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-05-23

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

SEC source: 0001213900-23-043121 · ownership.xml · derivative · entry 1

Newman James W. Jr. · CIK 0001718364 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-05-23

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

SEC source: 0001213900-23-043109 · ownership.xml · derivative · entry 1

Anderson J. Kermit · CIK 0001717983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-05-23

F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.

SEC source: 0001213900-23-045385 · ownership.xml · derivative · entry 1

Johnson Bankole A. · CIK 0001718158 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-05-23

SEC source: 0001213900-23-000003 · ownership.xml · nonDerivative · entry 1

Stilley William B. III · CIK 0001718069 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,020,979

F1 · shares: Represents the cancellation of 166,667 previously outstanding shares of restricted common stock of Adial Pharmaceuticals, Inc. originally issued on February 23, 2022.

F1 · balance_after: Represents the cancellation of 166,667 previously outstanding shares of restricted common stock of Adial Pharmaceuticals, Inc. originally issued on February 23, 2022.

SEC source: 0001213900-22-057513 · ownership.xml · nonDerivative · entry 2

Claiborne Cary J · CIK 0001370930 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100,000

F2 · price: The price reported is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.4079 through $0.4230, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.